The GLP-1 race is not slowing. A February pipeline snapshot tracks a higher-dose Wegovy, a potential heart-risk indication for Mounjaro, and the oral contender orforglipron, all moving through FDA review.
A February 2026 pipeline snapshot tracked several GLP-1 developments in FDA review: a higher-dose once-weekly Wegovy 7.2 mg (with stronger trial weight loss than the 2.4 mg dose), a potential new heart-risk-reduction indication for Mounjaro in type 2 diabetes, and the oral GLP-1 orforglipron, several under expedited pathways.
Even after the oral-pill milestone, the GLP-1 pipeline kept advancing, and February brought a useful status check.
Several decisions sit with the FDA, spanning higher doses and new uses.
A February pipeline update flagged a higher-dose once-weekly semaglutide, Wegovy 7.2 mg, supported by trial data showing greater average weight loss than the established 2.4 mg dose. It also tracked a potential new indication for tirzepatide (Mounjaro) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes, based on a dedicated cardiovascular outcomes trial, and continued review of the oral small-molecule GLP-1 orforglipron. Several of these were noted as moving under expedited or priority pathways.
The update also pointed to GLP-1s being studied well beyond weight and diabetes, including inflammatory and other conditions in earlier-stage trials, underscoring how broadly the class is expanding. As always, pipeline status is fluid: in review or in trials is not the same as approved or available, and decision timelines can move.
For consumers, a fuller pipeline means more future options but also more complexity and marketing noise. The useful habit is to treat pipeline news as a map of what may come, to be discussed with a prescriber, rather than a menu of things available today. Higher doses and new indications also carry their own benefit-and-risk profiles that apply to specific populations, not everyone.
Ahead, the key dates are the FDA decisions on the higher-dose Wegovy, the potential Mounjaro cardiovascular indication, and oral orforglipron; expedited pathways mean some could move relatively quickly. Earlier-stage studies in inflammatory and other conditions are worth watching as longer-horizon signals. Throughout, the same caution applies: a drug or dose in review is not available, and any new approval carries a benefit-and-risk profile specific to defined populations rather than a blanket recommendation.